We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Argon laser peripheral iridoplasty for topiramate-induced bilateral acute angle closure.
Journal of Glaucoma 2009 April
PURPOSE: To report a case of a topiramate-induced bilateral acute angle closure that was treated successfully by argon laser peripheral iridoplasty (ALPI).
METHODS: A 59-year-old healthy woman taking oral topiramate developed bilateral acute angle closure. B-scan ultrasonography, ultrasound biomicroscopy, and slit-lamp adapted ocular coherence tomography were performed.
RESULTS: The patient had shallow anterior chambers and total angle closure for 360 degrees OU. Ocular imaging showed circumferential ciliochoroidal effusions with anterior displacement of the iris-lens diaphragm. ALPI relieved the angle closure.
CONCLUSIONS: ALPI should be considered as initial therapy for topiramate-induced acute angle closure.
METHODS: A 59-year-old healthy woman taking oral topiramate developed bilateral acute angle closure. B-scan ultrasonography, ultrasound biomicroscopy, and slit-lamp adapted ocular coherence tomography were performed.
RESULTS: The patient had shallow anterior chambers and total angle closure for 360 degrees OU. Ocular imaging showed circumferential ciliochoroidal effusions with anterior displacement of the iris-lens diaphragm. ALPI relieved the angle closure.
CONCLUSIONS: ALPI should be considered as initial therapy for topiramate-induced acute angle closure.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app